WESTFORD, MASSACHUSETTS: Cynosure recently announced that the US Food and Drug Administration has cleared the company's Cellulaze Workstation for commercial distribution, giving millions of American women, what is said to be, the first minimally invasive solution against cellulite.
"Cellulaze is the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market," said Cynosure president and CEO Michael Davin. "Unlike those products, Cellulaze is the only aesthetic device that directly treats the physiological structure of cellulite, providing clinically proven, results."
An estimated 85% of women over the age of 20 [1,2] have some form of cellulite - pockets of fat deposited just beneath the surface of the skin, around the hips, thighs, and buttocks, which produces an "orange-peel" or a "cottage cheese" appearance. In the United States alone, the treatment of cellulite is a multibillion-dollar industry, according to market estimates. Cellulaze reduces cellulite - in just one treatment - by restoring the normal structure of the skin and underlying connective tissue. Cellulaze diminishes the lumpy pockets of fat, releases the areas of skin depression typifying cellulite and increases the elasticity and thickness of the skin.
Single-treatment aesthetic procedure
Nearly four years of clinical research puts Cellulaze in a class of its own: the only single-treatment aesthetic procedure clinically shown to reduce cellulite. Clinical data has demonstrated that Cellulaze treatments can increase the thickness of the skin by 25% and increase the elasticity of the skin by 29% at one year. No other anti-cellulite treatment has been proven to deliver these results.
"Based on the scientific data and the patient results we have observed over the past several years of evaluating the device, Cellulaze represents a new and highly effective standard of treatment for cellulite," said Barry E. DiBernardo, MD, a board certified plastic surgeon and clinical associate professor, Department of Surgery, Division of Plastic Surgery, University of Medicine and Dentistry of New Jersey. Dr. DiBernardo, one of five clinical investigators in a multi-center study of Cellulaze, has published one year results on a subset of the treated patients.
"The study was designed with both traditional, subjective measurements of clinical improvement and new objective, quantitative measures as well. All of the analysis led to the conclusion that patients treated with Cellulaze maintained results at least one year," said Dr. DiBernardo.
Proprietary SideLight 3D side-firing technology
Cellulaze uses a proprietary SideLight 3D side-firing technology to target the causes of cellulite beneath the skin: herniated pockets of fat, stiffened septae and thin skin. During the procedure, a tiny laser fiber is inserted under the skin, which gently heats the skin and disrupts or melts the fat. Next the laser releases the fibrous bands that create the dimpling effect from pulling down on the skin. This release creates a smoother look. Finally the laser's energy stimulates collagen production to increase skin's thickness and elasticity for a more even, healthier appearance.
Patients usually see improvements within a few weeks, with the most significant results continuing to develop for a few months following the procedure. Cellulaze also complements other body shaping technologies, such as Cynosure's Smartlipo family of workstations.
Cellulaze is also currently being marketed in Canada, the European Union, Australia and South Korea. Cynosure is pursuing regulatory approvals in additional international markets.
Sources:  Harvard Women's Health Watch Cellulite meltdown. Harv. Health Pub. Group 5, 7 (1998).  Sainio, E.L., Rantanen, T. and Kanerva, L. Ingredients and safety of cellulite creams. Eur. J. Dermatol. 10, 596- 603 (2000).  Drealos, Z.D. and Marenus, K.D. Cellulite: etiology and purported treatment. Dermatol. Surg. 23, 1177-1181 (1997).  DiBernardo, BE, "Treatment of Cellulite with One Year Follow-up using a 1440nm pulse laser" Aesthetic Surgery Journal, March 2011
LEGAL DISCLAIMER: This Message Board accepts no liability of legal consequences that arise from the Message Boards (e.g. defamation, slander, or other such crimes). All posted messages are the sole property of their respective authors. The maintainer does retain the right to remove any message posts for whatever reasons. People that post messages to this forum are not to libel/slander nor in any other way depict a company, entity, individual(s), or service in a false light; should they do so, the legal consequences are theirs alone. Bizcommunity.com will disclose authors' IP addresses to authorities if compelled to do so by a court of law.